Detalles de la búsqueda
1.
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Lancet Oncol
; 24(8): 892-902, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37429302
2.
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
BMC Cancer
; 23(1): 393, 2023 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37131154
3.
Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial.
Eur J Cancer
; 177: 103-111, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335780
4.
Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
Blood
; 112(10): 4039-47, 2008 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18753636
Resultados
1 -
4
de 4
1
Próxima >
>>